Since the early 2010s, monoclonal antibodies targeting CD19 and CD22 have been investigated in clinical trials for R/R B-ALL [6,7,8,9,10], leading to the approval of these agents as monotherapies in the salvage setting [9,10]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.